B

    BioRestorative Therapies Inc (BRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.20
    +0.00 (+1.66%)

    Market Cap: $5.16M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    -64.08%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.13 - $-0.13
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.23-76.9%
    7d ago$-0.23-76.9%
    Current$-0.13
    Revenue Consensus
    $370000
    Range$90000 - $650000
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    Revenue Consensus
    $387500
    Range$-707500 - $1M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 11
    		$-0.30$-0.15-100.00%Miss+0.0%
    Mar 26
    Reported May 14
    		$-0.12N/A+60.00%Beat+81.3%
    Dec 25
    Reported Mar 26
    		$-0.32$-0.34+5.88%Beat+14.7%
    Sep 25
    Reported Nov 12
    		$-0.33$-0.38+13.16%Beat-3200.0%
    Jun 25
    Reported Aug 12
    		$-0.30$-0.41+26.83%Beat-7.1%
    Mar 25
    Reported May 14
    		$-0.64$-0.32-100.00%Miss-8.5%
    Dec 24
    Reported Mar 27
    		$-0.38$-0.55+32.22%Beat+34.2%
    Sep 24
    Reported Nov 12
    		$-0.01N/A+97.14%Beat+98.4%
    Jun 24
    Reported Aug 13
    		$-0.28$-0.56+50.00%Beat+63.6%
    Mar 24
    Reported Jun 11
    		$-0.59$-0.51-15.69%Miss+61.4%
    Dec 23
    Reported Mar 29
    		$-0.57$-0.69+17.39%Beat+51.7%
    Sep 23
    Reported Nov 13
    		$-0.64$-0.68+5.88%Beat+50.0%
    Jun 23
    Reported Aug 11
    		$-0.77N/A+50.64%Beat+39.8%
    Mar 23
    Reported May 12
    		$-1.53$-1.26-21.43%Miss-11.7%
    Dec 22
    Reported Mar 24
    		$-1.18$-1.35+12.59%Beat+82.9%
    Sep 22
    Reported Nov 14
    		$-1.28$-1.45+11.72%Beat+74.3%
    Jun 22
    Reported Aug 15
    		$-1.28$-0.55-132.73%Miss+74.9%
    Mar 22
    Reported May 16
    		$-1.37$-0.63-117.46%Miss-13600.0%
    Dec 21
    Reported Mar 30
    		$-6.90$-0.54-1177.78%Miss-17150.0%
    Sep 21
    Reported Nov 15
    		$-4.99$-4.99+0.00%Beat-137.9%
    Jun 21
    Reported Aug 16
    		$-5.10N/AN/ABeat-170.8%
    Mar 21
    Reported May 17
    		$-0.01N/AN/ABeat+100.0%
    Dec 20
    Reported Mar 29
    		$-0.04N/AN/ABeat-406.3%
    Sep 20
    Reported Sep 30
    		$-2.10N/AN/ABeat-812.0%
    Jun 20
    Reported Jun 30
    		$7.21N/AN/ABeat+3105.5%
    Mar 20
    Reported Jun 29
    		$-31.46N/AN/ABeat-11135.4%
    Dec 19
    Reported Mar 30
    		$-0.01N/AN/ABeat+97.7%
    Sep 19
    Reported Nov 13
    		$-0.23N/AN/ABeat+41.0%
    Jun 19
    Reported Aug 14
    		$-0.24N/AN/ABeat+54.7%
    Mar 19
    Reported May 14
    		$-0.28N/AN/ABeat+15.2%
    Dec 18
    Reported Mar 29
    		$-0.35N/AN/ABeat+10.8%
    Sep 18
    Reported Nov 13
    		$-0.39N/AN/ABeat-5.4%
    Jun 18
    Reported Aug 14
    		$-0.53N/AN/ABeat-43.5%
    Mar 18
    Reported Apr 2
    		$-0.33N/AN/ABeat+35.1%
    Dec 17
    Reported Mar 31
    		$-0.39N/AN/ABeat+29.8%
    Sep 17
    Reported Nov 14
    		$-0.37N/AN/ABeat+17.5%
    Jun 17
    Reported Aug 14
    		$-0.37N/AN/ABeat-
    Mar 17
    Reported May 15
    		$-0.51N/AN/ABeat-
    Dec 16
    Reported Mar 21
    		$-0.56N/AN/ABeat-
    Sep 16
    Reported Nov 15
    		$-0.45N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.19EV/EBITDA0.13x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-14613.00%
    ROE-241.10%ROIC-289.87%
    Financial Health
    Debt/Equity0.01xInterest Coverage67.54x
    Current Ratio2.35xQuick Ratio2.35x
    Trading Statistics
    Beta0.74Avg Volume236.74K
    52-Week High$1.7352-Week Low$0.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.21
    SMA 20$0.21
    SMA 50$0.28
    SMA 200$0.54
    EMA 10$0.21
    EMA 20$0.22
    EMA 50$0.26
    EMA 200$0.55

    MACD

    Line: -0.02Signal: -0.02Hist: 0.00

    ADX

    ADX: 23.5+DI: 11.0-DI: 19.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down16.0
    PSAR$0.23

    Bollinger Bands

    Upper Band$0.23
    Lower Band$0.20
    %B Position1402%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    34.8

    Momentum Oscillators

    Stoch %K14.9
    Stoch %D27.7
    Williams %R-85.1
    ROC (10d)-8.0%
    Momentum-0.02
    CCI (20d)-146.1
    MFI (14d)53.8

    Volatility Measures

    ATR (14d)$0.02(10.5%)
    StdDev (20d)0.01
    Hist Vol49.6%(High)

    Volume Flow

    VWAP$0.20
    OBV876.6M
    AD Line-220.4M
    CMF (20d)-0.583

    Volume Metrics

    Avg Vol (20d)214.5K
    Vol Ratio1.0x
    VWMA (20d)$0.21

    Pivot Points

    R3$0.24
    R2$0.23
    R1$0.21
    Pivot Point$0.20
    S1$0.19
    S2$0.18
    S3$0.17

    Advanced Oscillators

    TSI-31.41
    Ultimate Osc26.8
    KST-217.06

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$23,170$19,600$11,800$303,300$25,000$43,300$233,600$89,100$35,000$19,300$30,700$64,500
    Cost of Revenue$7,385$1,636$10,570$8,729$2,909$3,339$18,243$6,490$0N/A$0$0
    Gross Profit$15,785$17,964$1,230$294,571$22,091$39,961$215,357$82,610$35,000$19,300$30,700$64,500
    Operating Expenses$3.40M$3.84M$3.71M$3.60M$4.83M$2.73M$2.50M$2.55M$4.14M$3.24M$3.14M$3.18M
    R&D$1.93M$3.56M$2.59M$2.23M$2.65M$2.74M$1.45M$1.45M$1.06M$1.09M$809,824$902,891
    SG&A$1.48M$283,552$1.12M$1.37M$2.18M$-11,316$1.05M$1.10M$3.09M$2.15M$2.33M$2.28M
    Operating Income$-3,385,733$-3,825,300$-3,709,011$-3,305,287$-4,807,534$-2,690,142$-2,286,993$-2,468,807$-4,109,252$-3,220,682$-3,104,443$-3,116,551
    Interest Income$0$0$0$0$100,608$0$0$0$0$0$0$0
    Interest Expense$0$-34,586$-57,740$-73,915$532,265$-118,988$-158,547$-175,945$-162,597$-376,223$-61,667$-96,187
    Income Before Tax$-2,154,405$-3,207,636$-3,038,277$-2,656,263$-5,339,799$-1,636,148$-1,091,416$-4,028,562$-2,223,255$-2,303,994$4.77M$-5,709,399
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,154,405$-3,207,636$-3,038,277$-2,656,263$-5,339,799$-1,636,148$-1,091,416$-4,028,562$-2,223,255$-2,303,994$4.77M$-5,709,399
    EBITDA$-2,107,490$-3,189,386$-3,043,397$-2,677,430$-5,388,626$-1,704,767$-1,201,694$-4,156,802$-2,343,139$-2,637,504$4.75M$-5,764,060
    EBIT$-2,159,884$-3,242,222$-3,096,017$-2,730,178$-5,440,407$-1,755,136$-1,249,963$-4,204,507$-2,385,852$-2,680,217$4.71M$-5,805,586
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BRTX

    News

    BioRestorative Therapies Received Notice of Noncompliance

    BioRestorative Therapies (BRTX) received a notice from Nasdaq for noncompliance with Listing Rule 5250(c)(1) due to its failure to timely file its Form 10-Q for Q2 2026. The company must submit a compliance plan by October 20, 2026, and may be granted an extension until February 16, 2027, to regain compliance and avoid delisting.

    TradingView•8/25/26•
    Bearish

    BioRestorative Therapies Inc expected to post a loss of 12 cents a share - Earnings Preview

    BioRestorative Therapies Inc (BRTX) is projected to report a loss of 12 cents per share. This earnings preview indicates the company's financial outlook for an upcoming report. The full article provides more details on this prediction.

    TradingView•8/19/26•
    Bearish

    BioRestorative Therapies suspends shipments of ExoCR and BioX products for review

    BioRestorative Therapies (NASDAQ:BRTX) has suspended all orders and shipments of its ExoCR and BioX biocosmeceutical product lines, effective August 7, pending a business review and regulatory assessment. The company, which has a market cap of $5.61 million and generated only $360,000 in revenue in the last twelve months, has not yet decided if sales will resume. This suspension comes amid negative investor reaction, with shares down significantly, and follows recent financial and strategic activities including a $1 million revolving loan and Kaos Capital acquiring a 4.9% stake.

    Investing.com•8/15/26•
    Bearish

    Form 8K BioRestorative Therapies Inc For: 14 August By Investing.com

    This article reports that BioRestorative Therapies Inc. filed a Form 8K on August 14th. The filing is brief and primarily serves as an announcement of this corporate action.

    Investing.com Nigeria•8/15/26•
    Neutral

    Form 8K BioRestorative Therapies Inc For: 14 August By Investing.com

    This article announces the filing of a Form 8K by BioRestorative Therapies Inc. on August 14. The brief notice from Investing.com indicates that the document is publicly available for review.

    Investing.com Canada•8/14/26•
    Neutral

    Frequently Asked Questions About BRTX

    Does BRTX pay dividends?
    BioRestorative Therapies Inc (BRTX) does not currently pay a regular dividend.
    What is BRTX's market cap?
    BioRestorative Therapies Inc (BRTX) has a market capitalization of $5.16M with a current stock price of $0.20.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In